| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8669173 | The Journal of Heart and Lung Transplantation | 2018 | 21 Pages |
Abstract
Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH. RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival. This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Raymond L. MD, Harrison W. MD, Adaani MD, Ekkehard MD, Marius M. MD, Dennis Dipl Stat, Christian MD, Sylvia MD, Hossein-Ardeschir MD,